Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A 20-Year Single-Center Experience

Background : Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment. We compared the periprocedural, short-, and long-term clinical outcomes and mortality predictors in hypertrophic obstructive cardiomyopathy patients who underwent alcohol septal ablation. Methods Hypertrophic obstructive cardiomyopathy patients aged ≥18 years (63 females and 71 males) who underwent alcohol septal ablation were included. The primary endpoint was all-cause mortality. Results The mean patient age was 60.0 (standard deviation 13.7) years. The median follow-up time was 13 (7.6-18.5) years. During the procedure, 9, 2, and 1 patients developed ventricular fibrillation, remote site myocardial infarction, and pericardial tamponade, respectively, but none died. One patient died during hospitalization. During the long-term follow-up, 17, 5, 20, and 8 patients developed heart failure, myocardial infarction, chronic atrial fibrillation, and non-fatal stroke, respectively, and 24 died. There was no significant difference between the sexes (all P > .05). Age (hazard ratio = 0.69, 95% CI = 0.61‒0.78, P < .001), body mass index (hazard ratio = 1.20, 95% CI = 1.04-1.40, P = .01), age at diagnosis (hazard ratio = 1.57, 95% CI = 1.34-1.78, P < .001), and time from diagnosis to ablation (hazard ratio = 1.57, 95% CI = 1.35-1.84, P < .001) predicted all-cause mortality. In Kaplan‒Meier curves, long-term all-cause mortality was similar in men and women (P[log-rank] = .43). Conclusion Alcohol septal ablation has similar short- and long-term outcomes for both sexes in hypertrophic obstructive cardiomyopathy patients. Risk factors for long-term mortality were age, body mass index, diagnosis age, and time delay to operation. Therefore, alcohol septal ablation timing is essential for better clinical outcomes. Our findings may contribute to the increased performance of alcohol septal ablation in hypertrophic obstructive cardiomyopathy patients in our country.

[1]  H. Bundgaard,et al.  Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. , 2021, International journal of cardiology.

[2]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[3]  M. Henein,et al.  Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.

[4]  H. Bundgaard,et al.  Alcohol septal ablation in patients with severe septal hypertrophy , 2019, Heart.

[5]  B. Wessler,et al.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. , 2019, Circulation. Cardiovascular interventions.

[6]  H. Seggewiss,et al.  Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[7]  M. Barbarawi,et al.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta‐analysis , 2018, Clinical cardiology.

[8]  B. Gersh,et al.  Hypertrophic Cardiomyopathy: Clinical Update. , 2018, JACC. Heart failure.

[9]  B. Gersh,et al.  Women with hypertrophic cardiomyopathy have worse survival , 2017, European heart journal.

[10]  F. Hang,et al.  Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China , 2017, Scientific Reports.

[11]  H. Bundgaard,et al.  Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. , 2017, JACC. Cardiovascular interventions.

[12]  A. Abizaid,et al.  Long‐term clinical follow‐up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  N. Smedira,et al.  Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. , 2015, Circulation. Cardiovascular imaging.

[14]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[15]  M. P. van den Berg,et al.  Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. , 2014, JACC. Cardiovascular interventions.

[16]  J. Veselka,et al.  Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. , 2014, European heart journal.

[17]  Ferhaan Ahmad,et al.  Female Sex Is Associated with Worse Prognosis in Patients with Hypertrophic Cardiomyopathy in China , 2014, PloS one.

[18]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[19]  O. Yavuzgil.  Septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A retrospective analysis , 2012 .

[20]  L. Køber,et al.  Long-Term Outcome of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: A Scandinavian Multicenter Study , 2011, Circulation. Cardiovascular interventions.

[21]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[22]  S. Ommen,et al.  Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score–matched cohort , 2019, The Journal of thoracic and cardiovascular surgery.

[23]  T. Berg,et al.  Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy A Single-Center Experience , 2014 .

[24]  M. Cheitlin.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Multicenter North American Registry , 2012 .